Saturday, August 24, 2019 | ePaper
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced that on Sunday, its co-founder, Lars Lannfelt, Professor in Geriatrics at Uppsala University and researcher, received one of the world's most prestigious awards in Alzheimer's disease research. The award is called the "Khalid Iqbal Lifetime Achievement Award in Alzheimer's Disease Research" and was given out during the ongoing Alzheimer's Association International ConferenceÂ® (AAICÂ®) 2019 in Los Angeles, USA.
The award recognises individuals whose contributions have shown a lasting impact on the field and whose body of work has demonstrated a lifetime commitment towards progress against Alzheimer's and dementia. Earlier this year, Professor Lannfelt was also the recipient of the Swedish Alzheimer's Foundation's Grand Research Prize.
The motivation for this international award, according to the Alzheimer's Association, is Professor Lannfelt's discoveries of mutations leading to understanding of the origins of Alzheimer's disease and his following research, which has led to the drug candidate BAN2401. In March this year, BioArctic's partner Eisai initiated a global confirmatory Phase 3 study with BAN2401 in patients with early Alzheimer's disease. This phase 3 study is based on the positive results from the Phase 2b study in 856 patients, which showed slowed clinical progression, clearance of amyloid beta in the brain and effects on neurodegenerative biomarkers, as well as good tolerability, after 18 months treatment.
"I am deeply grateful to receive the Khalid Iqbal Lifetime Achievement Award in Alzheimer's Disease Research from the Alzheimer Association. My thanks goes to the families and patients with Alzheimer's disease, who have contributed so much by participating in the research," said Lars Lannfelt at the award ceremony.
Professor Lannfelt received the award in Los Angeles from Dr. Khalid Iqbal himself, one of the co-founders of the Alzheimer's Association International Conference.
Gunilla Osswald PhD
CEO, BioArctic AB